MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring.

Area of Science:

• Oncology
• Biotechnology
• Molecular Diagnostics

Background:

• Cervical cancer remains a significant global health concern, with rising incidence rates.
• Current screening methods like cytology and HPV testing have limitations in sensitivity and reproducibility.
• There is a critical need for more reliable and sensitive diagnostic tools for early detection and precancerous lesion identification.

Purpose of the Study:

• To review the potential of liquid biopsy as a non-invasive diagnostic tool for cervical cancer.
• To highlight the role of microRNAs within extracellular vesicles as promising biomarkers.
• To emphasize the importance of advancing non-invasive methods for improved screening and treatment monitoring.

Main Methods:

• Review of current literature on cervical cancer diagnostics.
• Exploration of liquid biopsy techniques, including circulating tumor cells (CTCs), circulating free DNA (cfDNA), and microRNAs (miRNAs).
• Focus on microRNAs encapsulated in extracellular vesicles for biomarker analysis.

Main Results:

• Liquid biopsy offers a non-invasive alternative for analyzing cancer-derived products in biofluids.
• MicroRNAs, particularly those in extracellular vesicles, show significant potential as sensitive biomarkers.
• Liquid biopsy enables real-time monitoring of tumor progression, metastasis, and treatment response.

Conclusions:

• Liquid biopsy represents a promising advancement in cervical cancer diagnostics.
• Further research into microRNA-based liquid biopsies is crucial for enhancing screening and patient management.
• Non-invasive techniques are essential for improving outcomes in cervical cancer detection and treatment.